KRAS and neoplasm: INCB161734, another KRAS G12D(ON/OFF) inhibitor, demonstrated excellent oral bioavailability and potential efficacy in multiple types of G12D-mutated tumor xenograft models, resulting in significant tumor growth inhibition, growth arrest, and/or regression in multiple PDAC and CRC mouse tumor models.